1. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health, Radiological Devices Branch, Division of Reproductive, Abdominal, Ear, Nose and Throat, and Radiological Devices, Office of Device Evaluation. Guidance for industry: guidance for the submission of premarket notifications for magnetic resonance diagnostic devices. http://www.fda.gov/cdrh/ode/mri340.pdf. Updated November 14, 1998.Accessed January 3,2008.
2. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health, Radiological Devices Branch, Division of Reproductive, Abdominal, and Radiological Devices, Office of Device Evaluation. Guidance for industry and FDA staff: criteria for significant risk investigations of magnetic resonance diagnostic devices. http://www.fda.gov/cdrh/ode/guidance/793.html. Updated July 14, 2003.Accessed January 3,2008.
3. Kuhl CK, Traeber F, Gieseke J, et al. Whole-body high-field-strength (3.0-T) MR imaging in clinical practice. II. Technical considerations and clinical applications.Radiology (in press).
4. Sensitivity and Power Deposition in a High-Field Imaging Experiment
5. The Intrinsic Signal-to-Noise Ratio in Human Cardiac Imaging at 1.5, 3, and 4 T